Aligos Therapeutics, a South San Francisco clinical-stage biotechnology company, posted the single best quarterly income statement in its public history in the second quarter of 2026, and the reason is a deal rather than a product. In May 2026 the company licensed its lead hepatitis B drug pevifoscorvir sodium to the Chinese biotech Xiamen Amoytop for exclusive rights across Greater China, and it recognized $27.8 million of licensing revenue on that upfront payment in the quarter just ended. That one non-dilutive payment flipped an otherwise expected operating loss near $19 million into a net loss of just $1.5 million, or $0.14 per share, against a $15.9 million loss a year earlier. The quarter is a funding event wearing the clothes of a sales quarter, and it buys Aligos roughly a year of runway rather than a year of validated commercial traction.
The mechanism underneath the print is a cash-for-licensing trade that changes the company's near-term shape. Amoytop handed over $25.0 million net of tax in July 2026, which Aligos booked as revenue and as an outstanding receivable on the June 30 balance sheet, and Aligos stays entitled to up to $420 million in clinical, regulatory and sales milestones plus tiered high-single-digit royalties on any Chinese sales. That cash, layered on top of the $30.4 million in cash and equivalents on hand at quarter end, is what management says funds planned operations into the fourth quarter of 2026. We read the negotiation itself as the load-bearing event: Amoytop is paying to own pevifoscorvir sodium in China, validating the asset's data while simultaneously removing the largest single source of the company's cash need to fund that territory's clinical work.
The load-bearing risk is not efficacy, which now has meaningful supportive signals, but survival of the balance sheet, because the company again states that substantial doubt exists about its ability to continue as a going concern and that it needs to raise substantial additional capital before the fourth quarter ends. The falsifiable clock that tests the entire thesis is the next financing event, which the company's own liquidity language pins to late 2026, ahead of the topline data from the Phase 2 B-SUPREME hepatitis B study that management now guides to the final quarter of 2027. If Aligos secures a dilutive or non-dilutive capital infusion without destroying the fully diluted share count, and confirms the B-SUPREME enrollment and continuation signals that the spring interim analysis supported, the equity re-rates against a fully financed path to a regulatory catalyst; if the financing arrives too late or too dilutive, or interim efficacy data disappoint, the current roughly $43 million basic market capitalization is not a floor for the equity.